University of Chieti-Pescara

This Study Will Help Assess the Time Necessary for Tetranite® to Regenerate Bone in the Oral Environment LOWELL, Mass.--(BUSINESS WIRE)-- RevBio, Inc., announced that it has received approval from the Italian Ministry of Health and the Ethics Committee of the University “G.D'Annunzio” of Chieti-Pescara to start a 15-patient pilot clinical trial. The primary objective of this study will be to assess the time it takes for Tetranite®, the company’s adhesive biomaterial, to regenerate bone in the mandibular and maxillary dental arches. This press release features multimedia. View the full release here: Prior studies have demonstrated that TETRANITE® is replaced with bone via substitution as it dissolves, stimulating osteoblast cells to produce osteoid (bone precursor) which is then mineralized during the process of bone maturation. (Graphic: Business Wire) This study will be conducted at the Center for Advanced Studies and Technology (“CAST”) of the University “G.d’Annunzio” Chieti-Pescara under the leadership of Professor Sergio Caputi, MD, DDS, who serves as the Chancellor/Provost of the University. The research team also includes Professor Maurizio Piattelli, MD, DDS, Tonino Traini, DDS, PhD, Bruna Sinjari, DDS, PhD, Gianmaria D’Addazio, DDS, PhD, and Manlio Santilli, DDS, PhD Student. This team is part of the Department of Innovative Technologies in Medicine and Dentistry where novel and cutting-edge research in dentistry is conducted. “We are very pleased to see this study come together after much planning during the COVID-19 pandemic,” said Dr. Sinjari. “We have assembled a great research team which will be able to assess the unique osteoconductive properties of this biomaterial.” Currently there are no products approved in Europe or the United States that are adhesive to bone and capable of bonding dental implants into place while gradually resorbing and being replaced by new, native bone. These properties have been demonstrated in prior studies, but the focus of this study will be to assess the timescale when the material is resorbed by the human body, which will help determine the length of future clinical trials necessary for obtaining commercial approval. Dr. Paul Fugazzotto, DDS, an advisor to RevBio, and a noted lecturer, dental educator, and periodontist, introduced the company to the research team at the University of Chieti. “The design of this study will answer some important questions that will help evidence the key advantages of this biomaterial,” said Dr. Fugazzotto. “I believe this technology will be transformative in the way we place dental implants.” About RevBio, Inc. RevBio, Inc., is a clinical stage medical device company engaged in the development and commercialization of a patented, synthetic, injectable, self-setting, and osteoconductive bone adhesive biomaterial called Tetranite®. The company is initially developing this technology for use in the dental, cranial, and broader orthopaedic markets as well as applications in the animal health market. RevBio's Tetranite technology is not yet approved for commercial use. View source version on businesswire.com: Contacts Michael Tiedemann mtiedemann@revbio.com Source: RevBio, Inc. Smart Multimedia Gallery Photo Prior studies have demonstrated that TETRANITE® is replaced with bone via substitution as it dissolves, stimulating osteoblast cells to produce osteoid (bone precursor) which is then mineralized during the process of bone maturation. (Graphic: Business Wire) Logo View this news release and multimedia online at:

WASHINGTON--(BUSINESS WIRE)-- Altoida, Inc., a precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced the appointment of Dr. Antonella Santuccione Chadha as Chief Medical Officer. In this new role, Dr. Chadha will lead all clinical and medical affairs as the company continues to develop, validate, and commercialize its AI-driven digital biomarker platform. She will report directly to the Chief Executive Officer of Altoida, Travis Bond, and will serve on the Leadership team. Dr. Chadha is a medical doctor and internationally recognized expert in clinical pathology, neuroscience, neurological disease, and psychiatric disorders. She brings decades of global experience in clinical research and development, commercialization, patient engagement, and regulatory strategy. Prior to joining Altoida, Dr. Chadha served as the Head of Stakeholder Engagement for Alzheimer’s Disease at Biogen. She is the co-founder and pro-bono CEO of the Women’s Brain Project, a non-profit organization dedicated to addressing the influence of sex and gender on mental health, brain health, and neurological diseases. She is a decorated researcher, having studied novel immunotherapies for Alzheimer’s disease in the laboratory of Roger Nitsch and Christoph Hock at the University of Zurich where aducanumab, the first amyloid treatment for Alzheimer’s, was discovered. Her additional experience spans the Swiss Agency for Therapeutic Products, Roche Diagnostics and Roche Pharmaceuticals, the EU Commission Directorate for Health and Food Safety, the OECD, the CEOi, and several other Alzheimer’s Disease organizations. “Dr. Chadha is a true maverick in the field of neuroscience and a pioneer in utilizing precision technologies to improve the way we measure brain health and diagnose neurological diseases. She has led high-performing teams in the private, public, and non-profit sectors, and has a proven track record of success in R&D, clinical, and regulatory affairs,” said Travis Bond, Chief Executive Officer at Altoida. “She will be an invaluable asset to Altoida and our leadership team as we expand our platform and advance our deep pipeline of novel digital biomarkers for Alzheimer’s, and other neurological and neuropsychiatric disorders.” “I am thrilled to join Altoida at such a dynamic time. The company is developing its platform to improve patient outcomes across a breadth of neurological diseases, including Alzheimer’s. The company’s proprietary AI and augmented reality technology will be transformative in the early and accurate detection of Alzheimer’s and across the entire neurological disease drug development lifecycle. I look forward to working with Travis and the Altoida team to reduce the time and cost to diagnose complex and devastating conditions like Alzheimer’s, by bringing innovative, precise digital measurements and diagnostics to patients in need,” said Dr. Antonella Santuccione Chadha, Chief Medical Officer at Altoida. Dr. Chadha completed her Doctor of Medicine (M.D.) with a focus on Neuroscience at the University of Chieti, Italy. She continued her postgraduate education across several European universities such as the Center for Molecular Neurobiology in Hamburg and the University of Zurich. She is the author of several peer-reviewed papers about Alzheimer’s disease, policy applied to neuroscience, and the influence of sex and gender on mental and brain diseases. She continues to serve as a member of the scientific committee of the European College of Neuropsychopharmacology 2022 and pro bono Vice President of Euresearch. About Altoida, Inc. Altoida is building the world’s leading platform to accelerate and improve drug development, research, and care for patients with neurological diseases. The company’s innovative AI-driven approach leverages immersive augmented reality (AR) to evaluate the brain in a comprehensive, real-world mode of functioning using data captured with a standard smartphone or tablet. Altoida’s validated and evidence-based digital biomarker platform received FDA Breakthrough Device Designation and is supported by more than 20 years of scientific research and publications in journals like Nature Digital Medicine. Altoida is based in Washington, DC. For more information, visit . Follow us on LinkedIn and Twitter at @altoida.

HOBOKEN, N.J., Jan. 21, 2015 /PRNewswire/ -- New research delivers exciting news for those seeking natural ways to boost memory and mental performance. A study recently published in the Journal of Neurosurgical Sciences shows daily use of Pycnogenol® (pic-noj-en-all), a  natural plant extract from French maritime pine tree bark, may help improve attention span, memory, decision-making including executive-level performance and overall cognitive function. "This study finds Pycnogenol® to be a safe and effective natural option to improve day-to-day cognitive function, essentially serving as 'brain food' for executives, entrepreneurs and those who want help sharpening their decision-making. What is unique about this study is that it observes how Pycnogenol® can positively impact mood as participants reported feeling less anxiety and a stronger sense of content. That may be connected back to the mental performance boost and demonstrates the effects of dramatic reduction of oxidative stress," said physician and nutritional medicine expert Dr. Fred Pescatore. According to the National Center for Biotechnology Information1, the average American's attention span has reduced from 12 seconds (reported in 2000) to eight seconds, which can hurt productivity and quality of work produced. The peer-reviewed study conducted at Chieti-Pescara University in Italy and published in the December 2014 Journal of Neurosurgical Sciences, included 59 participants between ages 35 55, all of whom were generally fit and followed a healthy lifestyle. In the study, 30 participants supplemented Pycnogenol® 50mg/three times daily in combination with a controlled health plan; 29 participants in the control group followed the controlled health plan alone. The health plan involved regular sleep, balanced meals and daily exercise. While there is no single solution to improved cognitive function, lifestyle patterns and daily exercise routines have shown to increase attention span and improve mood.  In the study, after 12 weeks of daily supplementation with Pycnogenol®, results were also shown to: Significantly improve mood (16 percent increase Pycnogenol® / -2.1 percent control) Measurably boost mental performance (8.9 percent increase Pycnogenol® / 3.1 percent control) Advance sustained attention (13.4 percent increase) and memory (3.6 percent increase) Dramatically reduce oxidative stress (30 percent decrease Pycnogenol®) "This study completes a number of research observations indicating that Pycnogenol® can naturally help improve some aspects of cognitive functions throughout life. Multiple studies have been conducted using Pycnogenol® and showing its positive effects in managing and improving some attention parameters in children with ADHD, in improving results of specific cognitive test in students and in improving several aspects of cognitive functions in adults over 60," said Dr. Gianni Belcaro, lead researcher of the study.   "These latest findings are supported by decades of research on Pycnogenol®'s ability to naturally regulate oxidative stress levels (that may significantly affect some cognitive functions) and confirm the positive impact on overall cognitive function." Results of the study were measured using a self-administered visual analogue scale (VASL), national adult reading test (NART), special recognition memory (SRM) and Cambridge neuropsychological test to evaluate simple cognitive functions and levels of oxidative stress. "Participants who supplemented daily with Pycnogenol® demonstrated stronger performance in daily mental tasks such as dealing with money, managing people, and coping with stress. Those are mental performance benefits that can be felt from the home to the office and even in the classroom," said Dr. Pescatore. To review clinical research and additional information on Pycnogenol®, visit .  Pycnogenol® is available in more than 700 dietary supplements and multi-vitamins worldwide. About Pycnogenol® Pycnogenol® is a natural plant extract originating from the bark of the maritime pine that grows along the coast of southwest France and is found to contain a unique combination of procyanidins, bioflavonoids and phenolic acids, which offer extensive natural health benefits.  The extract has been widely studied for the past 40 years and has more than 340 published studies and review articles ensuring safety and efficacy as an ingredient. Today, Pycnogenol® is available in more than 700 dietary supplements, multi-vitamins and health products worldwide.  For more information, visit . About Horphag Research (USA) Inc. Horphag Research (USA) Inc., based in Hoboken, New Jersey, is the North American distributor for Pycnogenol® (pic-noj-en-all) brand French maritime pine bark extract on behalf of Horphag Research. Pycnogenol® is a registered trademark of Horphag Research Ltd. For its patented ingredient, Pycnogenol®, Horphag Research has been awarded the Frost & Sullivan Excellence in Research Award, Nutraceutical Business & Technology Safety & Quality Award, SupplySide West Scientific Excellence Award and The American Botanical Council's Tyler Research Award.  Horphag Research (USA) has the exclusive rights to market and sell Pycnogenol® in North America and benefits from more than 40 years of scientific research assuring the safety and efficacy of Pycnogenol® as a dietary supplement.  For more information about Pycnogenol® visit . 1 Attention Span Statistics. National Center for Biotechnology Information, U.S National Library of Medicine. Accessed at: .     Logo -  To view the original version on PR Newswire, visit: SOURCE Pycnogenol Help employers find you! Check out all the jobs and post your resume.